Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

Derry, Sheena; Moore, R. Andrew
January 2007
BMC Psychiatry;2007, Vol. 7, p40
Academic Journal
Background: Atypical antipsychotics are increasingly used for treatment of mental illnesses like schizophrenia and bipolar disorder, and considered to have fewer extrapyramidal effects than older antipsychotics. Methods: We examined efficacy in randomised trials of bipolar disorder where the presenting episode was either depression, or manic/mixed, comparing atypical antipsychotic with placebo or active comparator, examined withdrawals for any cause, or due to lack of efficacy or adverse events, and combined all phases for adverse event analysis. Studies were found through systematic search (PubMed, EMBASE, Cochrane Library), and data combined for analysis where there was clinical homogeneity, with especial reference to trial duration. Results: In five trials (2,206 patients) participants presented with a depressive episode, and in 25 trials (6,174 patients) the presenting episode was manic or mixed. In 8-week studies presenting with depression, quetiapine and olanzapine produced significantly better rates of response and symptomatic remission than placebo, with NNTs of 5-6, but more adverse event withdrawals (NNH 12). With mania or mixed presentation atypical antipsychotics produced significantly better rates of response and symptomatic remission than placebo, with NNTs of about 5 up to six weeks, and 4 at 6-12 weeks, but more adverse event withdrawals (NNH of about 22) in studies of 6-12 weeks. In comparisons with established treatments, atypical antipsychotics had similar efficacy, but significantly fewer adverse event withdrawals (NNT to prevent one withdrawal about 10). In maintenance trials atypical antipsychotics had significantly fewer relapses to depression or mania than placebo or active comparator. In placebo-controlled trials, atypical antipsychotics were associated with higher rates of weight gain of ≥7% (mainly olanzapine trials), somnolence, and extrapyramidal symptoms. In active controlled trials, atypical antipsychotics were associated with lower rates of extrapyramidal symptoms, but higher rates of weight gain and somnolence. Conclusion: Atypical antipsychotics are effective in treating both phases of bipolar disorder compared with placebo, and as effective as established drug therapies. Atypical antipsychotics produce fewer extrapyramidal symptoms, but weight gain is more common (with olanzapine). There is insufficient data confidently to distinguish between different atypical antipsychotics.


Related Articles

  • Pediatric and Adolescent Psychiatry.  // Current Medical Literature: Psychiatry;2006, Vol. 17 Issue 4, p133 

    The article offers observation on the study "A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents," by K. D. Wagner in a 2006 issue of the "American Journal of Psychiatry." It points out the limitations of the...

  • Lovastatin as an Adjuvant to Lithium for Treating Manic Phase of Bipolar Disorder: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Ghanizadeh, Ahmad; OmraniSigaroodi, Motahhar; Javadpour, Ali; Dabbaghmanesh, Mohammad Hossein; Shafiee, Sara // Depression Research & Treatment;2014, p1 

    Objectives. Many patients with bipolar disorder suffer from metabolic disorder. Lovastatin is effective for treating major depression. This double-blind randomized placebo controlled clinical trial investigates whether lovastatin is a useful adjuvant to lithium for treating mania. Methods....

  • Review: lithium reduces relapse rates in people with bipolar disorder. Geddes, J. R.; Burgess, S.; Hawton, K. // Evidence Based Mental Health;Aug2004, Vol. 7 Issue 3, p72 

    The article investigates whether lithium reduces relapse rates in people with bipolar disorder. The Cochrane Collaboration databases were used for this study. Randomised controlled trials (RCTs) of less than 3 months, comparing lithium with placebo for the maintenance of bipolar disorder were...

  • O tratamento farmacológico do transtorno bipolar: uma revisão sistemática e crítica dos aspectos metodológicos dos estudos clínicos modernos. Cheniaux, Elie // Revista Brasileira de Psiquiatria;mar2011, Vol. 33 Issue 1, p72 

    Objective: To review systematically the main clinical trials on the pharmacological treatment of bipolar disorder and to make a critical analysis of their methodological aspects. Method: A search in Medline, ISI and PsycINFO databases was conducted, using the following search terms: "bipolar",...

  • Development of a placebo effect model combined with a dropout model for bipolar disorder. Sun, Wan; Laughren, Thomas; Zhu, Hao; Hochhaus, Guenther; Wang, Yaning // Journal of Pharmacokinetics & Pharmacodynamics;Jun2013, Vol. 40 Issue 3, p359 

    The aim of this study was to develop a placebo model for bipolar disorder to help optimize clinical trial designs for studies targeting manic episodes in bipolar disorder. A bipolar disease database was built based on individual longitudinal data collected from over 3,000 patients in 11 clinical...

  • Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. Akhondzadeh, Shahin; Mohajari, Hassan; Mohammadi, Mohammad Reza; Amini, Homayoun // BMC Psychiatry;2003, Vol. 3, p7 

    Background: Bipolar disorder is a lifelong episodic condition characterized by mood swings between mania and depression. Several lines of evidence suggest that serotonin is likely to play a pivotal role in the pathophysiology of bipolar disorder. Ritanserin, a 5-HT2 receptor antagonist, has been...

  • The prevalence and significance of substance use disorders in bipolar type I and II disorder. Cerullo, Michael A.; Strakowski, Stephen M. // Substance Abuse Treatment, Prevention & Policy;2007, Vol. 2, p29 

    The aim of this paper is to provide a systematic review of the literature examining the epidemiology, outcome, and treatment of patients with bipolar disorder and co-occurring substance use disorders (SUDs). Articles for this review were initially selected via a comprehensive Medline search and...

  • Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Post, R. M.; Altshuler, L. L.; Leverich, G. S.; Frye, M. A.; Nolen, W. A.; Kupka, R. W.; Suppes, T.; McElroy, S.; Keck, P. E.; Denicoff, K. D.; Grunze, H.; Kitchen, C. M. R.; Mintz, J.; Walden, J // British Journal of Psychiatry;Aug2006, Vol. 189, p124 

    Background: Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression.Aims: To examine the relative acute effects of bupropion, sertraline and venlafaxine as adjuncts to...

  • Armodafinil Shows Potential Benefit for Depressive Symptoms in Bipolar Disorder. Hoyle, Brian // MD Conference Express;Jun2014, Vol. 14 Issue 8, p12 

    Armodafinil 150 mg daily for 8 weeks as an adjuvant with mood stabilizers and/or antipsychotic drugs improved depressive symptoms associated with bipolar I disorder. The benefits, however, were not statistically significant compared with placebo. The findings of a multi-institutional,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics